TuHURA Biosciences, Inc. (HURA) Dividend History

TuHURA Biosciences, Inc. is a biotechnology company focused on developing innovative therapies in the cancer treatment space. The company emphasizes research and development in immuno-oncology and targeted therapies, aiming to improve outcomes for patients with various cancer types.

Dividend History

TuHURA Biosciences, Inc. currently does not pay dividends

Company News

TuHURA R&D Jumps 75% in Q2

TuHURA Biosciences advanced its immuno-oncology pipeline in Q2 2025, launching a Phase 3 trial for IFx-2.0 in Merkel cell carcinoma and completing the Kineta acquisition. The company raised $15.5 million in equity financing to support ongoing clinical development.

The Motley Fool
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders

Halper Sadeh LLC is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed sales and mergers of The Shyft Group, MoneyLion Inc., TuHURA Biosciences, Inc., and Kineta, Inc.

Benzinga

Featured Companies: SHYF
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ML, PDCO, HURA, KANT on Behalf of Shareholders

Halper Sadeh LLC is investigating several companies, including MoneyLion Inc., Patterson Companies, Inc., TuHURA Biosciences, Inc., and Kineta, Inc., for potential violations of securities laws and breaches of fiduciary duties to shareholders related to proposed mergers and acquisitions.

GlobeNewswire Inc.

Page data last updated 08/19/2025 17:04:10 UTC